Test Price
2,800 AEDโ Home Collection Available
MYH7B Genetic Hearing Loss NGS Test in UAE | AED 2,800
Executive Summary & Core Metrics
Clinical Excellence & Patient Assurance:
โข 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing.
โข VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
โข Complimentary Telephonic Post-Test Clinical Guidance for result interpretation by a genetics specialist.
โข Direct Billing Verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
Our targeted Next-Generation Sequencing test thoroughly analyses the MYH7B gene for pathogenic variants linked to autosomal dominant non-syndromic sensorineural hearing loss. This advanced molecular diagnostic provides full gene coverage including CNV detection, offering a definitive genetic diagnosis for individuals and families with early-onset hearing impairment.
| Feature | Our MYH7B NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Targeted NGS (Full gene coverage, CNV detection) | Sanger sequencing (limited regions, no CNV) |
| Diagnostic Sensitivity | >99.9% for SNVs, indels, large deletions | ~95% for point mutations only |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Price | AED 2,800 (fixed, all-inclusive) | AED 3,500 โ 4,200 (fragmented additional charges) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
"MYH7B variants typically cause progressive, bilateral sensorineural hearing loss beginning in early childhood. Genetic confirmation allows for accurate prognostication, tailored audiological management, and informed family planning. All results must be correlated with a comprehensive audiogram and otologic evaluation before clinical decisions are made."
Medication Safety Advisory
โ ๏ธ Do not discontinue any prescribed medication without consulting your doctor. Self-adjustment of ototoxic drugs can worsen hearing loss.
Exclusion Criteria & Emergency Red Flags
Individuals with active febrile illness, ear infection, or inability to provide fully informed consent should defer sample collection. Seek immediate ENT review if you experience sudden hearing loss, vertigo, tinnitus, or facial nerve weakness. This genetic test is not designed for acute diagnostic emergencies.
Patient FAQ & Clinical Guidance
1. What is the MYH7B gene hearing loss test and who should consider it?
This genetic test identifies MYH7B gene variants causing autosomal dominant non-syndromic hearing loss. It is ideally suited for individuals with a family history of early-onset deafness or progressive sensorineural hearing loss of unknown origin.
2. How is the sample collected and is it painful?
A simple blood draw (3โ5 mL EDTA tube) or a one-drop FTA card blood spot is collected at your home by a DHA-licensed phlebotomist. The procedure is minimally invasive and no fasting is required.
3. How long will results take and how will I receive them?
Results are delivered securely within 3โ4 weeks via encrypted email, followed by a complimentary teleโgenetic counselling session to interpret the findings and discuss recommendations.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance: All genetic data is handled in full accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory processes are ISO 9001:2015 certified. The DHA-licensed facility operates under Licence No. 1143.
Clinical & Logistical Metadata
| Test Name | MYH7B Genetic Hearing Loss NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (3โ5 mL EDTA tube), Extracted DNA, or FTA Card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with CNV detection |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 101325-0 (MYH7B gene mutation analysis in blood) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians